---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-018212"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:28:51.935394+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Iovance Q4 2024 product revenue $73.7M; FY24 total $164.1M, achieving upper end of guidance

## Summary
- Full year 2024 product revenue of $164.1M, within $160-165M guidance; Amtagvi $103.6M, Proleukin $60.5M.
- Net loss FY24 $372.2M ($1.28/share) vs $444.0M ($1.89/share) in FY23.
- Reaffirms FY25 product revenue guidance of $450-475M; FY25 cash burn expected under $300M.
- Cash position ~$422M as of Feb 26, 2025, expected to fund operations into H2 2026.
- Dan Kirby named Chief Commercial Officer in Feb 2025; Raj Puri promoted to Chief Regulatory Officer Nov 2024.

## SEC filing metadata
- accession: 0001104659-25-018212
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465925018212/0001104659-25-018212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465925018212/tm257755d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-018212
- JSON: https://secwatch.observer/filing/0001104659-25-018212.json
- Plain text: https://secwatch.observer/filing/0001104659-25-018212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.